Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.1.01910
European Journal of Endocrinology, Vol 152, Issue 5, 749-756
Copyright © 2005 by European Society of Endocrinology
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diamanti-Kandarakis, E
Right arrow Articles by Mavrikakis, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diamanti-Kandarakis, E
Right arrow Articles by Mavrikakis, M

CLINICAL STUDY

Metformin administration improves endothelial function in women with polycystic ovary syndrome

E Diamanti-Kandarakis, K Alexandraki, A Protogerou1, C Piperi2, C Papamichael1, A Aessopos, J Lekakis1 and M Mavrikakis1

Laiko Hospital, Medical School, University of Athens, Endocrine Section, First Department of Medicine, Athens, Greece, 1 Alexandra University Hospital, Medical School, University of Athens, Vascular Laboratory, Department of Clinical Therapeutic, Athens, Greece and 2 Laboratory of Biological Chemistry, University of Athens Medical School, Athens, Greece

(Correspondence should be addressed to E Diamanti-Kandarakis, Athens University School of Medicine, Laiko, General Hospital, 1A Zefyrou str, Athens 14578, Greece; Email: akandara{at}otenet.gr)

Objective: The aim of this study was to investigate the endothelial status in young women with polycystic ovary syndrome (PCOS), using a simple and easily reproducible hemodynamic method combined with a biological marker and to evaluate the effect of metformin treatment on these parameters.

Design: Descriptive clinical trial.

Methods: Forty young women, 20 with PCOS and 20 normal women of similar age and body mass index were studied. Metformin (1700 mg daily) was administered for 6 months to the PCOS group. The endothelium status and the metabolic and hormonal profile were studied in both groups, as well as after metformin, by flow-mediated dilatation (FMD) on the brachial artery and by measurements of plasma endothelin-1 (ET-1) levels.

Results: FMD was impaired in the PCOS group when compared with controls (3.24±0.71% vs 8.81±1.07% respectively, P < 0.0001), but this difference normalized after metformin treatment (PCOSpost-metformin vs controls: 8.17±1.26 vs 8.81±1.07%, P = 0.70) since the values significantly improved after metformin treatment (PCOSpre-metformin vs PCOSpost-metformin: 3.24±0.71 vs 8.17±1.26%, P = 0.003). ET-1 levels were significantly higher in the PCOS women compared with the control group (7.23±0.50 vs 4.99±0.69 fmol/l, P = 0.01), they improved significantly after metformin treatment (PCOSpre-metformin vs PCOSpost-metformin: 7.23±0.50 vs 3.57±0.60 fmol/l, P < 0.0001) and their difference compared with the control group was reversed (PCOSpost-metformin vs controls: 3.57±0.60 vs 4.99±0.69 fmol/l, P = 0.13). Metformin administration improved hyperandrogenemia. However, in this study, mathematical methods used to assess insulin resistance failed to show any detected alteration after treatment with metformin.

Conclusions: PCOS women were found to exhibit endothelial dysfunction compared with controls, which was reversed 6 months after metformin administration.




This article has been cited by other articles:


Home page
Hum ReprodHome page
D. Romualdi, B. Costantini, L. Selvaggi, M. Giuliani, F. Cristello, F. Macri, A. Bompiani, A. Lanzone, and M. Guido
Metformin improves endothelial function in normoinsulinemic PCOS patients: a new prospective
Hum. Reprod., September 1, 2008; 23(9): 2127 - 2133.
[Abstract] [Full Text] [PDF]


Home page
Eur J EndocrinolHome page
E. Diamanti-Kandarakis, S. Livadas, S. A Kandarakis, A. Margeli, and I. Papassotiriou
Serum concentrations of atherogenic proteins neutrophil gelatinase-associated lipocalin and its complex with matrix metalloproteinase-9 are significantly lower in women with polycystic ovary syndrome: hint of a protective mechanism?
Eur. J. Endocrinol., April 1, 2008; 158(4): 525 - 531.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. Vollmert, S. Hahn, C. Lamina, C. Huth, M. Kolz, A. Schopfer-Wendels, K. Mann, F. Bongardt, J. C. Mueller, F. Kronenberg, et al.
Calpain-10 variants and haplotypes are associated with polycystic ovary syndrome in Caucasians
Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E836 - E844.
[Abstract] [Full Text] [PDF]


Home page
Hum ReprodHome page
E. Diamanti-Kandarakis, T. Paterakis, K. Alexandraki, C. Piperi, A. Aessopos, I. Katsikis, N. Katsilambros, G. Kreatsas, and D. Panidis
Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin
Hum. Reprod., June 1, 2006; 21(6): 1426 - 1431.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 European Society of Endocrinology.